JP2024523558A5 - - Google Patents
Info
- Publication number
- JP2024523558A5 JP2024523558A5 JP2023579538A JP2023579538A JP2024523558A5 JP 2024523558 A5 JP2024523558 A5 JP 2024523558A5 JP 2023579538 A JP2023579538 A JP 2023579538A JP 2023579538 A JP2023579538 A JP 2023579538A JP 2024523558 A5 JP2024523558 A5 JP 2024523558A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- composition according
- less
- compound
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213301P | 2021-06-22 | 2021-06-22 | |
| US63/213,301 | 2021-06-22 | ||
| US202163257907P | 2021-10-20 | 2021-10-20 | |
| US63/257,907 | 2021-10-20 | ||
| PCT/US2022/034574 WO2022271861A1 (en) | 2021-06-22 | 2022-06-22 | (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523558A JP2024523558A (ja) | 2024-06-28 |
| JP2024523558A5 true JP2024523558A5 (https=) | 2025-06-30 |
Family
ID=82693978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579538A Pending JP2024523558A (ja) | 2021-06-22 | 2022-06-22 | 脳腫瘍の治療における使用のためのｅｇｆｒの（１ｈ－ピロロ［２，３－ｂ］ピリジン－１－イル）ピリミジン－２－イル－アミノ－フェニル－アクリルアミド阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240293405A1 (https=) |
| EP (1) | EP4358957A1 (https=) |
| JP (1) | JP2024523558A (https=) |
| KR (1) | KR20240055717A (https=) |
| AU (1) | AU2022297453A1 (https=) |
| CA (1) | CA3224994A1 (https=) |
| WO (1) | WO2022271861A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4367116A4 (en) * | 2021-07-07 | 2025-04-30 | Crimson Biopharm Inc. | Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US20040171630A1 (en) * | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| KR101380190B1 (ko) | 2005-07-29 | 2014-04-11 | 콘서트 파마슈티컬즈, 인크. | 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 |
| WO2015188777A1 (en) * | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| WO2016105525A2 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| US20210101881A1 (en) * | 2018-02-12 | 2021-04-08 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Pyrimidine compound, preparation method thereof and medical use thereof |
-
2022
- 2022-06-22 EP EP22747175.2A patent/EP4358957A1/en active Pending
- 2022-06-22 AU AU2022297453A patent/AU2022297453A1/en active Pending
- 2022-06-22 KR KR1020247001434A patent/KR20240055717A/ko active Pending
- 2022-06-22 US US18/573,473 patent/US20240293405A1/en active Pending
- 2022-06-22 WO PCT/US2022/034574 patent/WO2022271861A1/en not_active Ceased
- 2022-06-22 CA CA3224994A patent/CA3224994A1/en active Pending
- 2022-06-22 JP JP2023579538A patent/JP2024523558A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034187A1 (en) | Sting agonistic compound | |
| JP5726190B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| TW200803867A (en) | Dosage forms and methods of treatment using a tyrosine kinase inhibitor | |
| JP2008509187A5 (https=) | ||
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| JP2006501201A5 (https=) | ||
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| EP2455080A1 (en) | S1P1 receptor agonists for use in the treatment of multiple sclerosis | |
| JP2024516353A5 (https=) | ||
| JP2024522183A5 (https=) | ||
| JP2005532397A5 (https=) | ||
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| JP2024523558A5 (https=) | ||
| JP2003516994A5 (https=) | ||
| RU2007106933A (ru) | Ингибиторы hsp90 | |
| US20240277722A1 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
| AU2009319050B2 (en) | Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor | |
| JP2010535203A5 (https=) | ||
| JP2025502240A5 (https=) | ||
| AU2003223958B2 (en) | Combinations comprising epothilone derivatives and alkylating agents | |
| ES2890924T3 (es) | Derivados de imidazol para el tratamiento de la hipertensión y/o la fibrosis | |
| RU2007115092A (ru) | Аминоспиртовые производные | |
| TWI343258B (en) | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative |